Total Payments
$458,775
2024 Payments
$506.70
Companies
49
Transactions
580
Medicare Patients
15,235
Medicare Billing
$4.5M
Payment Breakdown by Category
Other$286,767 (62.5%)
Consulting$105,354 (23.0%)
Travel$53,443 (11.6%)
Food & Beverage$12,869 (2.8%)
Education$342.43 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $280,027 | 118 | 61.0% |
| Consulting Fee | $105,354 | 64 | 23.0% |
| Travel and Lodging | $53,443 | 126 | 11.6% |
| Food and Beverage | $12,869 | 257 | 2.8% |
| Honoraria | $6,740 | 6 | 1.5% |
| Education | $342.43 | 9 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $135,018 | 122 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $84,409 | 92 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $65,457 | 70 | $0 (2021) |
| Celgene Corporation | $47,521 | 50 | $0 (2024) |
| Dova Pharmaceuticals | $27,023 | 17 | $0 (2021) |
| Janssen Biotech, Inc. | $14,879 | 22 | $0 (2022) |
| Pharmacyclics LLC, An AbbVie Company | $12,249 | 28 | $0 (2023) |
| Amgen Inc. | $11,763 | 21 | $0 (2019) |
| BeiGene USA, Inc. | $7,864 | 9 | $0 (2024) |
| ABBVIE INC. | $6,830 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $506.70 | 16 | Incyte Corporation ($117.73) |
| 2023 | $25,827 | 34 | E.R. Squibb & Sons, L.L.C. ($13,296) |
| 2022 | $30,049 | 40 | E.R. Squibb & Sons, L.L.C. ($21,004) |
| 2021 | $73,961 | 63 | Incyte Corporation ($20,727) |
| 2020 | $86,586 | 69 | Incyte Corporation ($22,230) |
| 2019 | $123,298 | 166 | Incyte Corporation ($40,198) |
| 2018 | $85,956 | 120 | AstraZeneca Pharmaceuticals LP ($36,119) |
| 2017 | $32,591 | 72 | Incyte Corporation ($11,901) |
All Payment Transactions
580 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $95.00 | General |
| 12/09/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: Oncology | ||||||
| 11/17/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $41.64 | General |
| Category: HEMATOLOGY | ||||||
| 11/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $41.51 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $30.69 | General |
| 11/08/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.59 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $33.25 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $35.87 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $28.25 | General |
| Category: Iron Deficiency Anemia | ||||||
| 07/30/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.55 | General |
| Category: Hematology | ||||||
| 07/11/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Incyte Corporation | JAKAFI (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $22.73 | General |
| Category: Hematology/Oncology | ||||||
| 05/07/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: Oncology | ||||||
| 04/24/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $27.51 | General |
| Category: Iron Deficiency Anemia | ||||||
| 03/21/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: ONCOLOGY | ||||||
| 03/07/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $25.09 | General |
| Category: Oncology | ||||||
| 11/29/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $34.59 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2023 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,910.00 | General |
| Category: Hematology/Oncology | ||||||
| 10/19/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $25.09 | General |
| Category: Oncology | ||||||
| 10/18/2023 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $29.51 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: Iron Deficiency Anemia | ||||||
| 10/10/2023 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $895.90 | General |
| Category: Hematology/Oncology | ||||||
| 10/10/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $120.84 | General |
| Category: Hematology/Oncology | ||||||
| 10/06/2023 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $30.46 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 59 | 4,094 | 147,725 | $4.1M | $1.5M |
| 2022 | 58 | 4,316 | 140,209 | $3.6M | $1.4M |
| 2021 | 62 | 3,600 | 135,930 | $2.6M | $915,989 |
| 2020 | 65 | 3,225 | 104,191 | $2.0M | $711,078 |
Total Patients
15,235
Total Services
528,055
Medicare Billing
$4.5M
Procedure Codes
244
All Medicare Procedures & Services
244 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 14 | 19,260 | $1.6M | $733,521 | 46.6% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 29 | 8,400 | $682,140 | $299,834 | 44.0% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 17 | 43,300 | $337,740 | $102,607 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 398 | 1,104 | $416,208 | $100,999 | 24.3% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 55 | 60,000 | $180,000 | $50,767 | 28.2% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 13 | 1,330 | $95,745 | $43,639 | 45.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 66 | 335 | $187,551 | $34,127 | 18.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 93 | 230 | $122,116 | $31,190 | 25.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 105 | 309 | $82,911 | $15,114 | 18.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 456 | 1,738 | $15,613 | $14,519 | 93.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 434 | 1,399 | $29,379 | $14,442 | 49.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 474 | 1,854 | $27,810 | $14,081 | 50.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 19 | 183 | $55,845 | $10,465 | 18.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 121 | 141 | $37,647 | $8,067 | 21.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 77 | 586 | $38,302 | $7,098 | 18.5% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 70 | 410 | $12,300 | $6,838 | 55.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $20,181 | $5,293 | 26.2% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 171 | 372 | $9,672 | $4,964 | 51.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 48 | 355 | $28,477 | $3,682 | 12.9% |
| 83550 | Iron binding capacity | Office | 2023 | 168 | 384 | $6,528 | $3,274 | 50.1% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 35 | 194 | $15,364 | $3,059 | 19.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 15 | 60 | $16,100 | $3,052 | 19.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 25 | 113 | $14,144 | $2,488 | 17.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 34 | 34 | $4,214 | $2,442 | 58.0% |
| 83540 | Iron level | Office | 2023 | 168 | 384 | $4,800 | $2,428 | 50.6% |
About Dr. John Winters, MD
Dr. John Winters, MD is a Hematology & Oncology healthcare provider based in Westbrook, Maine. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1366648693.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Winters, MD has received a total of $458,775 in payments from pharmaceutical and medical device companies, with $506.70 received in 2024. These payments were reported across 580 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($280,027).
As a Medicare-enrolled provider, Winters has provided services to 15,235 Medicare beneficiaries, totaling 528,055 services with total Medicare billing of $4.5M. Data is available for 4 years (2020–2023), covering 244 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Westbrook, ME
- Active Since 06/24/2007
- Last Updated 04/28/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1366648693
Products in Payments
- JAKAFI (Drug) $114,308
- CALQUENCE (Drug) $63,181
- OPDIVO (Biological) $44,055
- Doptelet (Drug) $27,023
- Pomalyst (Drug) $22,701
- REBLOZYL (Biological) $16,683
- Imbruvica (Drug) $12,114
- DARZALEX (Biological) $9,249
- ONUREG (Drug) $8,668
- Inrebic (Drug) $8,482
- BRUKINSA (Drug) $7,864
- IMBRUVICA (Drug) $7,785
- Luspatercept (Drug) $7,435
- MONJUVI (Drug) $7,193
- Kyprolis (Biological) $7,136
- EMPLICITI (Biological) $6,703
- ADCETRIS (Biological) $6,507
- Non-Covered $4,867
- Blincyto (Biological) $4,586
- Venclexta (Drug) $4,285
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Westbrook
Dr. Matthew Dugan, D.o, D.O
Hematology & Oncology — Payments: $766,946
Hematology & Oncology $766,946
Dr. Eleni Nackos, Md, MD
Hematology & Oncology — Payments: $105,209
Hematology & Oncology $105,209
Dr. Christian Thomas, Md, MD
Hematology & Oncology — Payments: $66,754
Hematology & Oncology $66,754
Dr. Tracey Weisberg, Md, MD
Hematology & Oncology — Payments: $31,532
Hematology & Oncology $31,532
Dr. Devon Evans, Md, MD
Hematology & Oncology — Payments: $31,195
Hematology & Oncology $31,195
Dr. Daniel Rausch, Md, MD
Hematology & Oncology — Payments: $27,394
Hematology & Oncology $27,394